

# FIRST STEMLAB PATENT FOR A TREATMENT WITH STEM CELLS

As a result of the investment in Research & Development, Stemlab holds a patent for a therapy based on stem cells.

The patent invention relates to a formulation in gel with stem cells from the umbilical cord blood for the treatment of chronic wounds in diabetics, a condition commonly known as “diabetic foot”.




Chronic wounds that can take months or years to heal

It is estimated that 10-15% of diabetic patients will suffer from chronic wounds over the course of their lifetime. There is currently no effective treatment for chronic wounds, which can lead to the amputation of a limb.

This type of wound affect over 340,000 patients in the United States and over 170 000 in Europe <sup>(1)</sup>.

This new therapy may represent hope for a disease with serious consequences for the patient’s quality of life, and that does not yet have an effective treatment.



Stemlab expects to complete the therapy development until 2018

(1)IMS Health